Suchergebnisse

With recent advances in the understanding of psoriatic disease, it is increasingly considered a systemic inflammatory
condition rather than limited to the skin and joints. A variety of biologics are available today for the treatment of psoriasis, but
with them, characteristics such as rapidity of onset, long-term efficacy, safety profile, and effects on comorbidities differ. We
designed an observational, non-interventional, retrospective study of patients with severe psoriasis receiving biologic treatment
with IL-17 inhibitors and aimed to investigate the correlations between etiopathogenic factors and the efficacy and persistence
of these therapies in a group of psoriasis patients from Romania. Study results show that patients treated with ixekizumab had
better persistence and high adherence compared to those treated with secukinumab. In this study, ixekizumab demonstrated
lower risks of non-persistence, discontinuation, and switching and a higher likelihood of high adherence compared with
secukinumab. This study contributes to the understanding of the persistence of anti-IL17 biologic therapies in psoriasis and the
factors that may influence it.